Acta Med. 2020, 63: 119-123
https://doi.org/10.14712/18059694.2020.29
Clinical Probe of Cyp2C8*2 Mutants in a Malaria Hyperendemic Zone: Evidence from North-Central, Nigeria
References
1. Jamison D, Feachem R, Makgoba M, et al.: The International Bank for Reconstruction and Development. Washington (DC): The World Bank 2006.
2. FEBS Letters 2011; 585(11): 1551–62.
< I, Eastman R, Lanzer M. Drug‐resistant malaria: Molecular mechanisms and implications for public health. https://doi.org/10.1016/j.febslet.2011.04.042>
3. Kumar SC. Drug Resistance in Malaria. In: Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. Springer 2017: 429–47.
4. Tropical Parasitology 2016; 6(1): 30.
HA, Parija SC. Antimalarial drug resistance: An overview.
5. J Infect Dis 2011; 204: 1772–8.
< GM, Gallo BC, Verra F, et al. Human genetic variation is associated with Plasmodium falciparum drug-resistance. https://doi.org/10.1093/infdis/jir629>
6. Pharmacogenomics 2007; 8(2): 187–98.
< JP, Gil BE. CYP2C8 and antimalaria drug efficacy. https://doi.org/10.2217/14622416.8.2.187>
<PubMed>
7. Drug Metabolism and Pharmacokinetics 2010; 25(1): 16–27.
< A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. https://doi.org/10.2133/dmpk.25.16>
8. Dermatologic therapy 2007, 20(4):160-174.
< S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. https://doi.org/10.1111/j.1529-8019.2007.00131.x>
<PubMed>
9. Drug Metabolism and Pharmacokinetics 2017; 32(3): 189–91.
< A, Bolaji OO, Kennedy MA. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. https://doi.org/10.1016/j.dmpk.2016.09.001>
10. Malaria Journal 2014; 13: 420.
< KJ, Schmidt T, Sjögren M, Minzi OMS, Kamugisha E, Swedberg G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. https://doi.org/10.1186/1475-2875-13-420>
<PubMed>
11. Malaria Journal 2012; 11: 125.
< GM, Gramolelli S, Tabacchi F. Distribution of human CYP2C8* 2 allele in three different African populations. https://doi.org/10.1186/1475-2875-11-125>
<PubMed>
12. Carrier Frequency Calculator (http://www.perinatology.com/calculators/Hardy-Weinberg.htm).
13. Current Infectious Disease Report 2010; 12(3): 165–73.
< JT, Juliano JJ, Wongsrichanalai C. Drug-Resistant Malaria: The Era of ACT. https://doi.org/10.1007/s11908-010-0099-y>
<PubMed>
14. Drug Metabolism and Pharmacokinetics 2016; 30: 1–3.
A, Bolaji OO, Kennedy MA. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population.
15. Prostate Cancer 2012: 798634.
P, Zeigler-Johnson CM, Spangler E, et al.: Androgen metabolism gene polymorphisms, associations with prostate cancer risk and pathological characteristics: a comparative analysis between south african and senegalese men.
16. Evolution, Medicine, and Public Health 2013; 2013(1): 118–34.
< RK. African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. https://doi.org/10.1093/emph/eot010>
<PubMed>
17. International Journal of Infectious Diseases 2019, 85: 49–53.
< SM, Ntoumi F, Vouvoungui C. Distribution of the cytochrome P450 CYP2C8*2 allele in Brazzaville, Republic of Congo. https://doi.org/10.1016/j.ijid.2019.04.035>
18. White NJ. Malaria. Edinburgh, United Kingdom: Elsevier Science Limited 2003.
19. Drug Metabolism and Disposition 2011; 39: 1546–54.
< BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. https://doi.org/10.1124/dmd.111.039065>
20. Pharmacological Reviews 2016; 68(1): 168–241.
< JT, Filppula AM, Niemi M, Neuvonen PJ. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. https://doi.org/10.1124/pr.115.011411>
21. Journal of Clinical Investigation 2008; 118(4): 1266–76.
< BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. https://doi.org/10.1172/JCI33996>
<PubMed>
22. Pharmacogenetics 2001; 11: 597–607.
< D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. https://doi.org/10.1097/00008571-200110000-00006>
23. Pharmacogenomics 2007; 8(2): 187–98.
< JP, Gil Berglund E. CYP2C8 and antimalaria drug efficacy. https://doi.org/10.2217/14622416.8.2.187>
<PubMed>
24. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences 1999: 354: 739–49.
< N. Antimalarial drug resistance and combination chemotherapy. https://doi.org/10.1098/rstb.1999.0426>
<PubMed>
25. PloS One 2016; 11(1): e0146908–e0146908.
< CO, Oyibo WA, Sutherland C, Hallet R, Oguike M. Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria. https://doi.org/10.1371/journal.pone.0146908>
<PubMed>